Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
36.58
-1.28 (-3.38%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Neurogene Market Cap
Neurogene has a market cap or net worth of $732.02 million as of August 28, 2026. Its market cap has increased by 160.42% in one year.
Market Cap
732.02M
Enterprise Value
514.97M
1-Year Change
160.42%
Ranking
Category
Stock Price
$36.58
ChartMarket Cap Chart
Since December 19, 2023, Neurogene's market cap has increased from $193.64M to $732.02M, an increase of 278.03%. That is a compound annual growth rate of 63.85%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 28, 2026 | 732.02M | 129.41% |
| Dec 31, 2025 | 319.09M | -6.03% |
| Dec 31, 2024 | 339.58M | 36.64% |
| Dec 29, 2023 | 248.52M | 28.34% |
| Dec 19, 2023 | 193.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Crescent Biopharma | 759.72M |
| Oculis Holding AG | 753.75M |
| Monopar Therapeutics | 751.02M |
| Phathom Pharmaceuticals | 729.17M |
| Bright Minds Biosciences | 721.39M |
| Shattuck Labs | 706.56M |
| Obsidian Therapeutics | 706.22M |
| BridgeBio Oncology Therapeutics | 700.72M |